170 results
Keyword Exelon - Capsula Remove keyword
-
List item
Withdrawn application: Exelon
rivastigmine, date of withdrawal: 21/11/2013, Post-authorisation, Last updated: 18/02/2014Exelon: Withdrawn application … marketing authorisation for Exelon and Prometax (rivastigmine … for the medicinal products Exelon and Prometax. The change … -
List item
Withdrawn application: Exelon
rivastigmine, date of withdrawal: 14/03/2012, Post-authorisation, Last updated: 19/04/2012Exelon: Withdrawn application … marketing authorisation for Exelon and Prometax harm Ltd … extension of indication for Exelon moderately severe Exelon and Prometax are medicines … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Exelon, rivastigmine
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Neurology
PIP number: EMEA-001084-PIP02-11, Route(s) of administration: Oral use, Transdermal use, Pharmaceutical form(s): Capsule, hard, Oral solution, Transdermal patch
Decision date: 27/04/2011, Last updated: 12/05/2011, Compliance check: XInvented name Exelon Prometax Active substance … waiver for rivastigmine (Exelon and Prometax) (EMEA-001084- PIP02-11 … waiver for rivastigmine (Exelon and Prometax) (EMEA-001084- PIP02-11 … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Exelon, rivastigmine
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Neurology
PIP number: EMEA-001084-PIP01-10, Route(s) of administration: Transdermal use, Pharmaceutical form(s): Transdermal patch
Decision date: 11/03/2011, Last updated: 08/04/2011, Compliance check: XInvented name Exelon Active substance rivastigmine … Rivastigmine Invented name: Exelon and Prometax Condition(s … size EU/1/98/06 6/019 Exelon 4.6 mg/24 h Transdermal … -
List item
Human medicine European public assessment report (EPAR): Exelon
rivastigmine, Dementia; Alzheimer Disease; Parkinson Disease
Date of authorisation: 11/05/1998, Revision: 46, Authorised, Last updated: 08/06/2023Exelon Nervous System Diseases Central … Exelon … summary for the public Exelon rivastigmine This is a … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): purified diphtheria toxoid, Purified Tetanus Toxoid, Five component acellular pertussis [Purified Pertussis Toxoid (PT), Purified Filamentous Haemagglutinin (FHA), Purified Fimbriae Types 2 and 3 (FIM), and Purified Pertactin (PRN)], Inactivated poliomyelitis vaccine (Vero) – Type 1 (Mahoney), Type 2 (MEF-1) and Type 3 (Saukett), Purified polyribosylribitol phosphate capsular polysaccharide of Haemophilus influenzae type b covalently bound to Tetanus protein (PRP-T)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Vaccines
PIP number: EMEA-000278-PIP01-08-M01, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Suspension for injection in pre-filled syringe, Suspension for injection in a vial
Decision date: 31/03/2009, Last updated: 18/05/2009, Compliance check: V, 18/09/2009polyribosylribitol phosphate capsular polysaccharide of Haemophilus … polyribosylribitol phosphate capsular polysaccharide of Haemophilus … polyribosylribitol phosphate capsular polysaccharide of Haemophilus … -
List item
Press release: Novartis Europharm Ltd withdraws its applications for an extension of the indication for Exelon and Prometax (rivastigmine)
Last updated: 15/03/2012extension of the indication for Exelon and Prometax (rivastigmine … centrally authorised medicines Exelon and Prometax (rivastigmine … marketing authorisations for Exelon and Prometax transdermal … -
List item
Human medicine European public assessment report (EPAR): Rivastigmine Actavis
rivastigmine hydrogen tartrate, Dementia; Alzheimer Disease; Parkinson Disease
Date of authorisation: 16/06/2011,
, Revision: 17, Authorised, Last updated: 05/07/2023
European Union (EU) called Exelon. What is Rivastigmine Actavis … to the reference medicine, Exelon. Two medicines are bioequivalent … and to be bioequivalent to Exelon. Therefore, the CHMP’s view … -
List item
Human medicine European public assessment report (EPAR): Nimvastid
rivastigmine, Dementia; Alzheimer Disease; Parkinson Disease
Date of authorisation: 11/05/2009,, Revision: 10, Authorised, Last updated: 22/02/2023
European Union (EU) called Exelon. What is Nimvastid used for … and to be bioequivalent to Exelon. Therefore, the CHMP’s view … CHMP’s view was that, as for Exelon, the benefit outweighs the … -
List item
Human medicine European public assessment report (EPAR): Rivastigmine Sandoz
rivastigmine, Dementia; Alzheimer Disease; Parkinson Disease
Date of authorisation: 10/12/2009, Revision: 14, Authorised, Last updated: 25/09/2023capsules and oral solution of Exelon, a medicine that is already … EU). The company that makes Exelon has agreed that its scientific … contact dermatitis’ to Exelon patch. Why has Rivastigmine … -
List item
Human medicine European public assessment report (EPAR): Rivastigmine Hexal
rivastigmine, Dementia; Alzheimer Disease; Parkinson Disease
Date of authorisation: 11/12/2009, Revision: 15, Authorised, Last updated: 21/06/2023capsules and oral solution of Exelon, a medicine that is already … EU). The company that makes Exelon has agreed that its scientific … contact dermatitis’ to the Exelon patch in the past. Why has … -
List item
Human medicine European public assessment report (EPAR): Rivastigmine 1 A Pharma
rivastigmine, Alzheimer Disease; Dementia; Parkinson Disease
Date of authorisation: 11/12/2009, Revision: 15, Authorised, Last updated: 21/06/2023capsules and oral solution of Exelon, a medicine that is already … EU). The company that makes Exelon has agreed that its scientific … contact dermatitis’ to Exelon patch. Why has Rivastigmine … -
List item
Human medicine European public assessment report (EPAR): Nimenrix
Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid, Meningitis, Meningococcal
Date of authorisation: 20/04/2012, Revision: 36, Authorised, Last updated: 17/07/2023contains small amounts of capsular polysaccharides (sugars from … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 December 2013
CHMP, Last updated: 20/12/2013Exelon … -
List item
Referral: Cyklo-f
tranexamic acid, Article 29(4) referrals
Status: European Commission final decision, opinion/position date: 25/05/2000, EC decision date: 12/09/2000, Last updated: 27/07/2000Cyklo-f is supplied as white, capsular film coated tablets containing … 1999. Cyklo-f is supplied as white, capsular film coated tablets containing … -
List item
National expert: Kai-Uwe Riedel, Medical Products Agency (updated)
- Declaration of interests - 39.21 KB | PDF
- Curriculum Vitae - 28.05 KB | PDF
electrons to Rhodobacter capsulatus nitrogenase. Eur.J.Biochem … purple bacterium Rhodobacter capsulatus. J Mol Microbiol Biotechnol … fixation in Rhodobacter capsulatus: identification of new anf … -
List item
Human medicine European public assessment report (EPAR): Prometax (updated)
rivastigmine, Alzheimer Disease; Parkinson Disease; Dementia
Date of authorisation: 03/12/1998, Revision: 46, Authorised, Last updated: 21/11/2023extension of the indication for Exelon and Prometax (rivastigmine … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 April 2011
CHMP, Last updated: 15/04/2011Rivastigmine Actavis is a generic of Exelon. … Actavis is a generic of Exelon. Positive opinions for extensions … -
List item
Press release: European Medicines Agency: Committee for Medicinal Products for Human Use 10-13 October 2005
CHMP, Last updated: 13/10/2005Exelon … recommended that the indication of Exelon and Prometax (rivastigmine … with Parkinson’s disease. Exelon was first authorised in the … -
List item
National expert: Sebastiaan Hoekema, Health And Youth Care Inspectorate (updated)
- Declaration of interests - 41.42 KB | PDF
- Curriculum Vitae - 30.73 KB | PDF
α_proteo bacterium Rhodobacter capsulatus. The emphasis was on the photo_biological … α_proteo bacterium Rhodobacter capsulatus. Further details are provided … light_use by Rhodobacter capsulatus continuous cultures in a … -
List item
National expert: Andreas Sundgren, Norwegian Medicines Agency (updated)
- Declaration of interests - 39.22 KB | PDF
- Curriculum Vitae - 28.55 KB | PDF
Streptococcus pneumoniae Type 14 Capsular Polysaccharide Structures … -
List item
National expert: Anne-Mette Hoberg, Danish Medicines Agency (updated)
- Declaration of interests - 39.42 KB | PDF
- Curriculum Vitae - 28.67 KB | PDF
preparations from Methylococcus capsulatus (Bath) comprise methanol … -
List item
Human medicine European public assessment report (EPAR): Apexxnar (updated)
Pneumococcal polysaccharide serotype 1, Pneumococcal polysaccharide serotype 3, Pneumococcal polysaccharide serotype 4, Pneumococcal polysaccharide serotype 5, Pneumococcal polysaccharide serotype 6A, Pneumococcal polysaccharide serotype 6B, Pneumococcal polysaccharide serotype 7F, Pneumococcal polysaccharide serotype 8, Pneumococcal polysaccharide serotype 9V, Pneumococcal polysaccharide serotype 10A, Pneumococcal polysaccharide serotype 11A, Pneumococcal polysaccharide serotype 12F, Pneumococcal polysaccharide serotype 14, Pneumococcal polysaccharide serotype 15b, Pneumococcal polysaccharide serotype 18C, Pneumococcal polysaccharide serotype 19A, Pneumococcal polysaccharide serotype 19F, Pneumococcal polysaccharide serotype 22F, Pneumococcal polysaccharide serotype 23F, Pneumococcal polysaccharide serotype 33F, Pneumococcal Infections
Date of authorisation: 14/02/2022,
, Revision: 6, Authorised, Last updated: 27/11/2023
-
List item
Human medicine European public assessment report (EPAR): Champix
varenicline, Tobacco Use Cessation
Date of authorisation: 25/09/2006, Revision: 38, Authorised, Last updated: 31/10/2023 -
List item
Human medicine European public assessment report (EPAR): Prevenar 13 (updated)
Pneumococcal polysaccharide serotype 1, Pneumococcal polysaccharide serotype 3, Pneumococcal polysaccharide serotype 4, Pneumococcal polysaccharide serotype 5, Pneumococcal polysaccharide serotype 6A, Pneumococcal polysaccharide serotype 6B, Pneumococcal polysaccharide serotype 7F, Pneumococcal polysaccharide serotype 9V, Pneumococcal polysaccharide serotype 14, Pneumococcal polysaccharide serotype 18C, Pneumococcal polysaccharide serotype 19A, Pneumococcal polysaccharide serotype 19F, Pneumococcal polysaccharide serotype 23F, Pneumococcal Infections; Immunization
Date of authorisation: 09/12/2009, Revision: 45, Authorised, Last updated: 27/11/2023